Overview

A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)

Status:
Completed

Trial end date:
2019-03-15

Target enrollment:

Participant gender:

Summary

This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem™ in subjects with mild dementia due to Alzheimer's Disease. Subjects will be randomized to receive either 10mg once daily Xanamem™ or Placebo at a 1:1 ratio in a double-blinded fashion.

Phase:

Phase 2

Details

Lead Sponsor:

Actinogen Medical

Collaborator:

ICON Clinical Research